©Author(s) (or their employer(s)) 2026.
World J Gastrointest Surg. Feb 27, 2026; 18(2): 114607
Published online Feb 27, 2026. doi: 10.4240/wjgs.v18.i2.114607
Published online Feb 27, 2026. doi: 10.4240/wjgs.v18.i2.114607
Table 1 Comparison of patient baseline characteristics, n (%)/mean ± SD
| Item | Total (n = 80) | Nutritional risk group (n = 37) | Non-nutritional risk group (n = 43) | χ²/t | P value |
| General clinical data | |||||
| Gender | 0.089 | 0.765 | |||
| Male | 49 (61.2) | 23 (62.2) | 26 (60.5) | ||
| Female | 31 (38.8) | 14 (37.8) | 17 (39.5) | ||
| Age (years) | 62.4 ± 11.2 | 63.8 ± 10.9 | 61.2 ± 11.4 | 1.084 | 0.282 |
| BMI (kg/m2) | 22.3 ± 3.8 | 21.1 ± 3.4 | 23.3 ± 3.9 | -2.765 | 0.007 |
| Smoking history | 34 (42.5) | 17 (45.9) | 17 (39.5) | 0.331 | 0.565 |
| Drinking history | 28 (35.0) | 14 (37.8) | 14 (32.6) | 0.237 | 0.626 |
| Comorbidities | |||||
| Hypertension | 31 (38.8) | 16 (43.2) | 15 (34.9) | 0.579 | 0.447 |
| Diabetes | 18 (22.5) | 9 (24.3) | 9 (20.9) | 0.125 | 0.724 |
| Cardiovascular disease | 12 (15.0) | 7 (18.9) | 5 (11.6) | 0.835 | 0.361 |
| Tumor-related data | |||||
| Tumor location | 2.341 | 0.505 | |||
| Fundus | 8 (10.0) | 5 (13.5) | 3 (7.0) | ||
| Body | 22 (27.5) | 11 (29.7) | 11 (25.6) | ||
| Antrum | 42 (52.5) | 18 (48.6) | 24 (55.8) | ||
| Total stomach | 8 (10.0) | 3 (8.1) | 5 (11.6) | ||
| Gross type | 3.247 | 0.355 | |||
| Ulcerative | 45 (56.2) | 22 (59.5) | 23 (53.5) | ||
| Fungating | 18 (22.5) | 8 (21.6) | 10 (23.3) | ||
| Infiltrative | 14 (17.5) | 5 (13.5) | 9 (20.9) | ||
| Stenotic | 3 (3.8) | 2 (5.4) | 1 (2.3) | ||
| Histological type | 4.892 | 0.180 | |||
| Well-differentiated adenocarcinoma | 15 (18.8) | 5 (13.5) | 10 (23.3) | ||
| Moderately-differentiated adenocarcinoma | 28 (35.0) | 12 (32.4) | 16 (37.2) | ||
| Poorly-differentiated adenocarcinoma | 31 (38.7) | 17 (45.9) | 14 (32.6) | ||
| Signet ring cell carcinoma | 6 (7.5) | 3 (8.1) | 3 (7.0) | ||
| T stage | 3.892 | 0.273 | |||
| T1 | 12 (15.0) | 4 (10.8) | 8 (18.6) | ||
| T2 | 23 (28.8) | 9 (24.3) | 14 (32.6) | ||
| T3 | 31 (38.7) | 16 (43.2) | 15 (34.9) | ||
| T4 | 14 (17.5) | 8 (21.6) | 6 (14.0) | ||
| N stage | 4.537 | 0.103 | |||
| N0 | 22 (27.5) | 8 (21.6) | 14 (32.6) | ||
| N1 | 26 (32.5) | 10 (27.0) | 16 (37.2) | ||
| N2 | 19 (23.8) | 11 (29.7) | 8 (18.6) | ||
| N3 | 13 (16.2) | 8 (21.6) | 5 (11.6) | ||
| TNM stage | 5.847 | 0.054 | |||
| Ib | 12 (15.0) | 3 (8.1) | 9 (20.9) | ||
| II | 35 (43.8) | 14 (37.8) | 21 (48.8) | ||
| III | 33 (41.2) | 20 (54.1) | 13 (30.2) | ||
| Vascular invasion | 38 (47.5) | 21 (56.8) | 17 (39.5) | 2.379 | 0.123 |
| Neural invasion | 29 (36.2) | 16 (43.2) | 13 (30.2) | 1.436 | 0.231 |
| Preoperative CEA (ng/mL) | 8.2 ± 15.3 | 10.1 ± 18.2 | 6.7 ± 12.1 | 1.015 | 0.313 |
| Preoperative CA19-9 (U/mL) | 42.8 ± 86.4 | 51.7 ± 102.3 | 35.2 ± 71.8 | 0.852 | 0.397 |
| Preoperative CA72-4 (U/mL) | 15.6 ± 32.4 | 19.8 ± 38.7 | 12.1 ± 26.2 | 1.038 | 0.302 |
- Citation: Zhou K, Tu RF, Lu LH, Zhang H. Impact of nutritional status on treatment completion and prognosis during adjuvant chemotherapy following gastric cancer surgery. World J Gastrointest Surg 2026; 18(2): 114607
- URL: https://www.wjgnet.com/1948-9366/full/v18/i2/114607.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v18.i2.114607